Saltar al contenido
Merck

Alleviation of Toxicity Caused by Overactivation of Pparα through Pparα-Inducible miR-181a2.

Molecular therapy. Nucleic acids (2017-12-17)
Yanjie Cheng, Zhuying Wei, Shengsong Xie, You Peng, Yi Yan, Dan Qin, Shenghui Liu, Yanling Xu, Guangpeng Li, Lisheng Zhang
RESUMEN

Widely varied compounds, including certain plasticizers, hypolipidemic drugs (e.g., ciprofibrate, fenofibrate, WY-14643, and clofibrate), agrochemicals, and environmental pollutants, are peroxisome proliferators (PPs). Appropriate dose of PPs causes a moderate increase in the number and size of peroxisomes and the expression of genes encoding peroxisomal lipid-metabolizing enzymes. However, high-dose PPs cause varied harmful effects. Chronic administration of PPs to mice and rats results in hepatomegaly and ultimately carcinogenesis. Nuclear receptor protein peroxisome proliferator-activated receptor-α (Pparα) was shown to be required for this process. However, biological adaptations to minimize this risk are poorly understood. In this study, we found that miR-181a2 expression was induced by the Pparα agonist WY-14643. Moreover, exogenous expression of miR-181a-5p dramatically alleviated the cell toxicity caused by overactivation of Pparα. Further studies showed that miR-181a-5p directly targeted the Pparα 3' untranslated region and depressed the Pparα protein level. This study identified a feedback loop between miR-181a-5p and Pparα, which allows biological systems to approach a balance when Pparα is overactivated.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
GW7647, ≥98% (HPLC)